| name | teplizumab-eligibility-and-course |
| description | Decide whether a person with confirmed early-stage type 1 diabetes qualifies for teplizumab (Tzield) — the anti-CD3 disease-modifying antibody that delays progression from Stage 2 to Stage 3 T1D — and outline the 14-day intravenous course, expected benefit, regulatory status, and pre-treatment work-up. Use when a clinician asks whether a patient with early T1D qualifies for teplizumab, indication for Tzield, Stage 2 T1D what treatment is available, how to delay onset of T1D, is teplizumab available for a child with autoantibodies, HbA1c 6.0% and GAD-positive is this teplizumab territory, or is planning the disease-modifying treatment pathway for early-stage T1D. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569) and the underlying TN-10 trial data (Herold et al, NEJM 2019 and long-term extension). |
Teplizumab (Tzield) — Eligibility & Course
Assess whether a person with early-stage T1D qualifies for the anti-CD3 monoclonal antibody teplizumab, and plan the 14-day IV course. Teplizumab is the first and currently only approved disease-modifying therapy that delays clinical (Stage 3) T1D.
Step 1 — Confirm the indication is Stage 2 T1D
Teplizumab is approved only for Stage 2 T1D. Verify:
| Criterion | Requirement |
|---|
| Autoantibodies | ≥2 confirmed islet autoantibodies (from GAD65, IAA, IA2, ZnT8), each positive on a second sample using 2 independent methods |
| Glycaemia | Dysglycaemia below ADA diagnostic thresholds — Stage 2a (FPG 5.6–6.9 mmol/L / 100–124 mg/dL, or 2h OGTT 7.8–11.0 mmol/L / 140–198 mg/dL, or HbA1c 39–47 mmol/mol / 5.7–6.4%) or Stage 2b (as 2a PLUS CGM time >7.8 mmol/L / >140 mg/dL of >10%) |
| Symptoms | Asymptomatic — no osmotic symptoms (polyuria, polydipsia, weight loss), no DKA presentation |
| Age | Approved in ages 8 years and above (FDA). Local regulator may vary — check the label |
If the person is at Stage 1 (autoantibody positive but normoglycaemic) → NOT eligible at this time. Continue monitoring; retest glycaemia at each visit to detect progression to Stage 2.
If the person is at Stage 3 (already meets ADA diagnostic criteria for diabetes) → NOT the approved indication for teplizumab. At Stage 3, standard insulin therapy applies; the disease-modifying effect is smaller and outside the current approved label. Trials continue in Stage 3 with other agents (abatacept, ATG, golimumab, baricitinib, verapamil).
Step 2 — Confirm regulatory availability where you practise
| Region | Status |
|---|
| USA (FDA) | Approved November 2022 for Stage 2 T1D in patients ≥8 years |
| Canada (Health Canada) | Approved |
| UK (MHRA) | Approved |
| EU (EMA) | Approved; accepted for FDA National Priority Voucher pilot program |
| India (CDSCO) | Not yet approved as of 2026 — access is by named-patient / compassionate use / import route only. Verify with the manufacturer or local regulatory contact before promising availability |
| Other regions | Check the local regulator; approval status is changing quickly |
Practical implication: even where the drug is approved, cost and access remain limiting. Discuss availability, price, insurance / public-payer coverage, and drug-import logistics before raising expectations with the family.
Step 3 — Assess for contraindications and complications risk
Before infusion, check:
- Active or recent infection — teplizumab causes transient lymphopaenia; defer during active infection
- History of severe hypersensitivity to teplizumab (contraindication)
- Pregnancy / breastfeeding — insufficient safety data; avoid unless benefit clearly outweighs
- Recent live vaccine — hold live vaccines from 8 weeks before through 52 weeks after teplizumab; inactivated vaccines from 2 weeks before through the treatment course. Update the vaccination schedule proactively
- Pre-existing chronic viral infection (EBV, CMV, HIV, HBV, HCV) — active or reactivation risk; specialist input
- Baseline blood tests:
- CBC with differential (baseline lymphocyte count)
- Liver function tests (LFTs)
- EBV serology if not previously documented
- Consider CMV, HBV, HCV per local protocol
- Pregnancy test in females of childbearing potential
Step 4 — The 14-day intravenous course
Standard regimen: teplizumab once daily IV infusion for 14 consecutive days.
- Dosing: weight-based per label — starts at a lower dose day 1 (65 μg/m²), escalates through day 5 (250 μg/m²) then maintenance to day 14
- Route: intravenous over approximately 30 minutes; monitoring during and after infusion
- Premedication (per label to reduce infusion reactions):
- Antipyretic (paracetamol/acetaminophen)
- Antihistamine
- Antiemetic
- Monitoring during infusion: vital signs, infusion-reaction watch, hypersensitivity
- Monitoring post-course:
- CBC weekly during and shortly after the course (lymphopaenia expected; usually recovers)
- LFTs during and after the course
- Watch for cytokine release syndrome, serum sickness, rash, headache
Step 5 — Set expectations for benefit
From TN-10 trial data (Herold et al):
- Median time to Stage 3 T1D: 48.4 months (teplizumab) vs 24.4 months (placebo). Roughly a 2-year delay
- Hazard ratio 0.41 for progression to Stage 3
- Diagnosis of Stage 3 by end of primary follow-up: 43% (teplizumab) vs 72% (placebo)
Extended follow-up (median 923 days):
- Median time to Stage 3: 59.6 months (teplizumab) vs 27.1 months (placebo)
- 50% of teplizumab-treated remained diabetes-free vs 22% of placebo (HR 0.46)
- Improved β-cell function — C-peptide preserved on teplizumab, declined in placebo
- Improvement in C-peptide correlated with reduced T-cell secretion of IFNγ and TNFα (mechanistic support)
Communicate honestly to the family:
- Teplizumab delays Stage 3 T1D — it does not permanently prevent it (in most people)
- On average about 2 years of extra insulin-free life
- Some people benefit more, some less; individual response varies
- Preservation of β-cell function may translate to easier T1D management even after progression (less brittle glycaemia, lower HbA1c, potentially fewer complications long-term)
- No proven long-term reduction in microvascular / macrovascular complications yet — data will accrue over decades
Step 6 — Plan post-course monitoring
After the 14-day course:
- Continue routine early-stage T1D monitoring — regular glucose monitoring (CGM), HbA1c, education, psychological support
- Symptom surveillance — the person is still at risk of progression; osmotic symptoms warrant urgent evaluation
- Retest CBC/LFTs per label
- Watch for infusion-related delayed effects — serum sickness, rash, cytokine effects can appear days after
- Vaccination catch-up — resume inactivated vaccines after the specified interval, live vaccines only after 52 weeks post-course
- Second course — a retreatment course is not currently a standard indication in the approved label; investigational
Guardrails
- Teplizumab is a specialist infusion — not something to initiate outside a centre with disease-modifying-therapy infrastructure for autoimmune diabetes. Refer to a T1D specialist / research centre if your unit lacks the infrastructure
- Do not offer teplizumab in Stage 1 — outside the approved indication, evidence is limited and the risk/benefit is unfavourable
- Do not offer teplizumab after Stage 3 — outside the approved indication, insulin is the standard
- A single unconfirmed autoantibody positive is NOT an indication — verify with the mandatory two-sample two-method confirmation first (see
t1d-islet-autoantibody-screening-confirmation)
- Screen for pre-existing infection carefully — post-teplizumab lymphopaenia can reactivate latent viral infections. EBV in particular deserves attention
- Manage vaccine timing PROACTIVELY — a child scheduled for live MMR / varicella boosters, or an adolescent scheduled for HPV, needs their schedule reviewed against the 8-weeks-before / 52-weeks-after live-vaccine rule. Missed windows delay the course or delay the vaccines
- Communicate the ~2-year delay honestly — the drug is not a cure. Families may hear "delays T1D" and expect prevention; use the actual numbers (48.4 vs 24.4 months; 50% still diabetes-free at long-term follow-up vs 22%)
- Cost, access, and geography matter — do not raise expectations before confirming the drug is actually obtainable and affordable in the person's country / insurance / import pathway
- Psychosocial support is not optional — the Stage 2 diagnosis + a 14-day IV course is a significant intervention on a still-asymptomatic child. Anxiety, family stress, school disruption, and adherence issues are common. Involve a psychologist / diabetes educator from the start
- Monitor for delayed adverse events (cytokine release, serum sickness, prolonged lymphopaenia) — not all reactions happen during infusion
- Document the batch number and any concomitant medications in the record — biological product traceability
Related MD2SKILL skills
t1d-staging-classifier — must classify to Stage 2 before considering teplizumabt1d-islet-autoantibody-screening-confirmation — the confirmed-antibody status is a prerequisitediabetes-vaccination-checker — coordinate vaccine schedule around the live-vaccine window
Source
Hussain S, Tree T, Mathieu C, Klupa T, Tuomaala A-K, de Wit M, Kordonouri O, Braune K, Pall J, Castano L, Besser REJ, Galhardo J, Ulivi F, Bosi E, Bogdanovic U, Alabert C, Battelino T. An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation. Diabetes, Obesity and Metabolism. 2026;28:3535–3556. DOI: 10.1111/dom.70569. Open-access under Creative Commons Attribution (CC-BY). Section 4 "Potential for immunotherapy of early-stage T1D".
Underlying trial: Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019;381:603-613. TN-10 study; long-term follow-up published subsequently.
